Imiquimod: A Review
Background and Objective: Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. It exhibits antiviral and antitumor effects; however, it does not exhibit direct antiviral effects in vitro. By inducing cytokines, such as interferon a, imiquimod stimulates both the innate immune response and the cellular arm of acquired immunity. Currently, imiquimod is approved for use in the treatment of external genital and perianal warts in adults. Conclusion: Beyond its established use, there are case reports and preliminary studies suggesting the effectiveness of imiquimod 5% cream in the treatment of nongenital human papillomavirus warts, molluscum contagiosum, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, Bowen's disease, nongenital human papillomavirus infection, and vulvar intraepithelial neoplasia..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2002 |
|---|---|
| Erschienen: |
2002 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Journal of cutaneous medicine and surgery - 6(2002), 6 vom: Dez., Seite 554-560 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Gupta, Aditya K. [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Antiviral Activity |
| Anmerkungen: |
© Canadian Dermatology Association 2002 |
|---|
| doi: |
10.1007/s10227-001-0134-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2065787791 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2065787791 | ||
| 003 | DE-627 | ||
| 005 | 20230518140402.0 | ||
| 007 | tu | ||
| 008 | 200820s2002 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s10227-001-0134-6 |2 doi | |
| 035 | |a (DE-627)OLC2065787791 | ||
| 035 | |a (DE-He213)s10227-001-0134-6-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.93$jDermatologie |2 bkl | ||
| 100 | 1 | |a Gupta, Aditya K. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Imiquimod: A Review |
| 264 | 1 | |c 2002 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Canadian Dermatology Association 2002 | ||
| 520 | |a Background and Objective: Imiquimod (Aldara) is an immune response modifier used primarily to treat anogenital warts. Imiquimod induces cytokines and enhances cell-mediated cytolytic antiviral activity in vivo. It exhibits antiviral and antitumor effects; however, it does not exhibit direct antiviral effects in vitro. By inducing cytokines, such as interferon a, imiquimod stimulates both the innate immune response and the cellular arm of acquired immunity. Currently, imiquimod is approved for use in the treatment of external genital and perianal warts in adults. Conclusion: Beyond its established use, there are case reports and preliminary studies suggesting the effectiveness of imiquimod 5% cream in the treatment of nongenital human papillomavirus warts, molluscum contagiosum, actinic keratosis, basal cell carcinoma, squamous cell carcinoma, Bowen's disease, nongenital human papillomavirus infection, and vulvar intraepithelial neoplasia. | ||
| 650 | 4 | |a Squamous Cell Carcinoma | |
| 650 | 4 | |a Innate Immune Response | |
| 650 | 4 | |a Antiviral Activity | |
| 650 | 4 | |a Basal Cell Carcinoma | |
| 650 | 4 | |a Response Modifier | |
| 700 | 1 | |a Browne, Melanie |4 aut | |
| 700 | 1 | |a Bluhm, Robyn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cutaneous medicine and surgery |d Springer-Verlag, 1996 |g 6(2002), 6 vom: Dez., Seite 554-560 |w (DE-627)225015609 |w (DE-600)1361720-5 |w (DE-576)102016410 |x 1203-4754 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2002 |g number:6 |g month:12 |g pages:554-560 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s10227-001-0134-6 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a GBV_ILN_2004 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 936 | b | k | |a 44.93$jDermatologie |q VZ |0 106410040 |0 (DE-625)106410040 |
| 951 | |a AR | ||
| 952 | |d 6 |j 2002 |e 6 |c 12 |h 554-560 | ||